Pharmaceutical Pricing Disputes and Medicare Negotiation Impacts
- Reports
- 4
- Developments
- 7
- Repetition
- 0%
New informationRepeats or wire copies
What happened
The Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit against the federal government, arguing that Medicare’s drug pricing program illegally imposes foreign price controls. Separately, Biktarvy was added to Medicare negotiated prices starting in 2028. Furthermore, a U.S. House committee began investigating AbbVie and Merck regarding trials conducted in China.
From zerohedge.com, cnbc.com
Why it matters
The negotiations between Medicare and drugmakers affect market stability and revenue streams for pharmaceutical companies. PhRMA claims the pricing program risks future medical innovation and patient access. The regulatory actions and legal challenges introduce market risk for major drug producers.
CMS published the premium totals for Medicare on June 21, 2026.
From zerohedge.com, cnbc.com
Who's involved
- AbbViePharmaceutical company subject to a U.S. House committee probe regarding China trials.
- MerckPharmaceutical company subject to a U.S. House committee probe regarding China trials.
- CMSAgency responsible for implementing drug pricing changes and is a defendant in the lawsuit.
- Gilead SciencesAmerican company whose HIV franchise sales reached $6.249B in the third quarter.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Gilead SciencesSpeculative
Medicare negotiated pricing might constrain the revenue stream from drugs like Biktarvy.
- AbbVieSpeculative
The U.S. House committee probe could negatively impact the stock price of AbbVie.
- MerckSpeculative
The U.S. House committee probe could negatively impact the stock price of Merck.
- CMSSpeculative
CMS implementing negotiated prices could constrain market revenue for pharmaceutical companies.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Medicare drug pricing changes may alter UnitedHealth Group's costsUnitedHealth Group's operational costs and reimbursement rates may shift due to Medicare drug pricing changes.Possible
- Novo Nordisk may face market pressure from US drug pricing shiftsNovo Nordisk may face market share pressure from US drug pricing policy shiftsPossible
How it developed
Newest first. Tap a step to see who reported it.Biktarvy added to Medicare negotiated prices from 20281 source
PhRMA initiated legal action challenging Medicare's drug pricing policies.1 source
- The Administration negotiated confidential deals on drug prices using HHS officials, involving major pharmaceutical companies.Sub-event
- Medicare reimbursement rules affect market stability for Nuo Therapeutics, Inc.Sub-event
- Medicare negotiates volume discounts on drugs, while lobbying efforts block government cost-trimming.Sub-event
Digital Realty Trust bought into data centers from Blackstone, while Reuters reported on a U.S. House committee probe into drugmakers, involving AbbVie and Merck.1 source
Big pharma companies are negotiating pricing exemptions due to Medicare system changes.1 source
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
-
Merck
public company in Indonesia